Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (1074)	12/17/1997 3:49:00 AM
From: Bill Wexler	Respond to of 7041

Understanding ED...and why ZONA is a complete scam: uspharmacist.com It's interesting to note that Zonagen relied on deceiving naive investors by obfuscating the fact that the active ingredients in its ED solution is not proprietary. Both Vivus and Zonagen are trying to sell new delivery systems. In Vivus's case, the company also benefited from the fact that the FDA approved alprostadil for the treatment of ED. Zonagen - of course - is relying on the oral delivery of phentolamine - which is ineffective. It is easy to see why Zonagen has been playing smoke and mirrors with the Phase II and III results.

To: BDR who wrote (1074)	12/17/1997 4:20:00 AM
From: Bill Wexler	Read Replies (2) \| Respond to of 7041

Zona's own patent opines that oral administration is inferior!!! This little gem comes from the Zorgniotti/Zonagen patent which only covers the transmucosal, intranasal, transdermal, or rectal administration of vasodilators but not oral. In fact the patent explains why oral administration is inferior!!!! Start reading at line 50 in the right column... patent.womplex.ibm.com

To: BDR who wrote (1074)	12/17/1997 11:35:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 7041

Dale Rusell, check posts # 920 and 921. scientific peer review articles on oral and buccal articles fully available and patents and Zonagen's claims started on this clinical research. I do not considered them enough to get a definite answer, still more data will be good to had (even from those articles)but they are the only full publications available. Not great results, but one could not conclude from here that the product is completely worthless, it works better than). But safety is a big problem, not huge as I initially thought but a definite limitation. Post # 918 also has some pharmacology information about phentolamine. Base on those two studies I am not a long. I will wait for FDA approval, or the actual Zona studies publication (not too late to make money). If I short it will not be based on this studies either, but in the dynamics of the market and for that I do not short, I fell confortable going long if I like something. But since most drugs actually failed them I am inclined this one will failed too. I am not willing to take this risk, but willing to wait. Where is the "White Paper" is it out? Not yet?